Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) antibody

Details for Product No. ABIN152058
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms FLK1, CD309, VEGFR, VEGFR2, Vegfr-2, FLK-1, flk-1, FLK/KDR, vegfr-2, KDR
Reactivity
Human, Mouse (Murine)
(481), (292), (195), (64), (63), (52), (49), (26), (4), (2), (2), (2), (2), (2), (2), (2), (2), (1)
Host
Rabbit
(437), (82), (35), (3), (3), (2)
Clonality
Polyclonal
Conjugate
Un-conjugated
(39), (10), (8), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (4), (4), (3), (3), (2), (1), (1), (1), (1)
Application
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Western Blotting (WB)
(381), (169), (148), (137), (83), (78), (60), (48), (36), (30), (8), (8), (4), (3), (2), (1)
Pubmed 2 references available
Catalog no. ABIN152058
Quantity 0.1 mL
Price
Contact our Customer Service for availability and price in your country.
Shipping to United States (Change)
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This antibody was made to residues corresponding to the kinase insert or C-terminus ofmurine VEGFR-2 (residues 1158-1365).
Specificity This antibody is specific for VEGFR-2. Species Reactivity: This antibody reacts with mouse and human VEGFR-2 proteins. Other species havenot been tested.
Cross-Reactivity Human, Mouse (Murine)
Purification Affinity Purified
Alternative Name CD309 / VEGFR-2 / Flk-1
Background VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activationplays an essential role in a large number of biological processes such as embryonicdevelopment, wound healing, cell proliferation, migration and differentiation. Like othergrowth factor receptors, upon ligand binding VEGF receptor 2 dimerises and isautophosphorylated on multiple tyrosine residues. These sites can be involved in theregulation of kinase activity or serve as binding sites for SH2 and phosphotyrosinebinding containing signaling proteins. Phosphorylation of Tyrosines 1054 and 1059 inthe activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosinekinase activity. Alternate Names: anti-VEGFR2 antibody, anti-VEGFR 2 antibody, anti-Protein-tyrosine kinase receptorflk-1 antibody, anti-Fetal liver kinase 1 antibody, anti-Kinase NYK antibody, anti-FLK1antibody, anti-KDR antibody, anti-Kinase insert domain receptor antibody, anti-KRD1antibody, anti-Ly73 antibody, anti-Protein tyrosine kinase receptor FLK1 antibody,anti-Vascular endothelial growth factor receptor 2 antibody.
Gene ID 3791, 3791
Research Area Cytokines, Receptors
Application Notes Suggested working dilutions: immunoprecipitation 2-5 ul,Western Blot 1:2,000-1:10,000
Restrictions For Research Use only
Format Liquid
Buffer Preservative: Sodium Azide.
Preservative Sodium azide
Storage 4 °C
Supplier Images
anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) antibody anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) antibody
General Rahimi, Dayanir, Lashkari: "Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells." in: The Journal of biological chemistry, Vol. 275, Issue 22, pp. 16986-92, 2000 (PubMed).

Meyer, Singh, Rahimi: "The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling." in: The Journal of biological chemistry, Vol. 279, Issue 1, pp. 735-42, 2003 (PubMed).

Hosts (437), (82), (35), (3), (3), (2)
Reactivities (481), (292), (195), (64), (63), (52), (49), (26), (4), (2), (2), (2), (2), (2), (2), (2), (2), (1)
Applications (381), (169), (148), (137), (83), (78), (60), (48), (36), (30), (8), (8), (4), (3), (2), (1)
Conjugates (39), (10), (8), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (4), (4), (3), (3), (2), (1), (1), (1), (1)
Epitopes (45), (42), (42), (39), (26), (19), (17), (15), (12), (10), (7), (7), (6), (5), (4), (4), (4), (4), (4), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top